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Epidemiology of valvular 
heart diseases in Africa
ETIOLOGY OF RHEUMATIC FEVER                          
The current understanding of the pathogenesis RF is that RF is 
the result of a delayed immune response to Group A B-haemo-
lytic streptococcus (GABHS) pharyngitis after a latent period 
ranging from 1-5 weeks.(8) Our understanding of this current 
working paradigm is based on epidemiologic and experimental data 
largely from the United States(9,10) more than half a century ago 
when RF and RHD were still a major public health problem 
there. Rheumatic fever rarely affects adults and occurs mainly in 
children in the age group 5-15 years.(11,12) About 3% of GABHS 
pharyngitis cases will develop RF of left untreated, but the risk of 
RF increases substantially to about 75% with a recurrent episode 
of GABHS pharyngitis.(13-15) The precise pathogenic mechanism 
of RF has not been fully defi ned.(2)
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INTRODUCTION                                                              
One of the earliest cases, if not the fi rst case, of rheumatic fever 
(RF) with rheumatic heart disease (RHD) reported in Africa was 
reported by medical offi cers Procter and Hargreaves in 1932 in 
the East African Medical Journal.(1) One of the medical offi cers 
had been engaged in native practice(1) for eleven years while the 
other had examined a large number of African school children and 
neither had found a case of RF or RHD prior. The reported 
case was that of a 25 year old male from Lumbwa, Kenya 
admitted to a local hospital with two months duration of painful 
and swollen joints and a fever. On physical examination, both a 
systolic and a diastolic murmur were heard consistent with left-
sided valvular regurgitation. Infective endocarditis was ruled out 
since the patient’s condition improved with bed rest and sali-
cylates. He was dismissed after about a week of admission and 
was advised to seek follow up upon discharge.(1)  In the 76 years 
since that case report, RF and RHD have become a major but 
under-appreciated public health problem in Africa where they 
account for signifi cant cardiac morbidity and mortality in a substantial 
number of children and young adults.(2-7)
Rheumatic heart disease (RHD) resulting from rheumatic 
fever (RF) is the main form of valve disease in Africa. Other 
forms of valve diseases such as myxomatous mitral valve 
disease, age-related valve disease, sub-valvular aneurysms or 
valve disease related to endomyocardial fi brosis are less 
common than RHD. In developed countries, RF and RHD are 
rare and no longer pose a public health problem, but the 
combination of poverty, lack of awareness, lack of 
infrastructure and resources, and social instability contribute 
to the persistence of RF and RHD in Africa. The presence of 
other major infectious diseases also shifts attention away 
from RF and RHD. Contemporary population-based 
epidemiologic data utilising echocardiography to detect 
valve disease suggests the prevalence of valve diseases in 
Africa is likely much higher than previously thought, meaning 
the estimated mortality, morbidity and socio-economic 
burden they cause could also be much higher than currently 
appreciated. Increased efforts are needed to defi ne the scope 
of the problem of valve diseases in Africa to draw attention 
to these illnesses and step up public health efforts to control 
and eradicate them as has already been achieved in other 
parts of the world. This article highlights the public health 
problem of valve diseases in Africa, the efforts underway to 






















Intriguing data from Australian aborigines affected by high 
incidence of RF suggests GABHS pyoderma or even non-
GABHS may be responsible for RF and RHD in that population.(16) 
However, similar data from other high incidence populations 
does not exist.(17)
SEQUELAE OF RHEUMATIC FEVER AND                   
RHEUMATIC HEART DISEASE
Rheumatic fever affects multiple organs, and the clinical presenta-
tion is variable depending on multiple factors including the organs 
affected, severity of involvement and the time of presentation.(18) 
The diagnosis of RF is based on the 2002-2003 World Health 
Organisation (WHO) revised Jones criteria.(2,19)  
Cardiac involvement in RF may be pancarditis, and it is cardiac 
involvement in the form of valvulitis that is the most important 
cause of morbidity and mortality.(20) There is evidence of cardiac 
involvement during the acute episode in 40 to 80% of cases of 
acute RF21,(21-23) but cardiac involvement almost always occurs in 
recurrent episodes of RF.(24) A large majority of those who have 
carditis during RF episodes will develop progressive RHD from 
infl ammation and scarring of the heart valves, typically left-sided, 
which may result in signifi cant valvular regurgitation and or 
stenosis and heart failure in childhood or early adulthood.(25) 
Determinants of the outcome of RHD are the age of fi rst attack 
of RF and the frequency and severity of recurrent attacks.(26) 
Cardiac involvement in the attack of RF may range from mild to 
severe and should be suspected on clinical grounds when a 
murmur (systolic or diastolic) is heard on physical examination or 
if there is presence of cardiomegaly or unexplained heart 
failure.(18)
Hospital-based studies and cause of death studies across Africa 
are all consistent and show that RHD is the main cause of 
cardiac morbidity and mortality in children and young adults,(4) 
with heart failure being the predominant cause of morbidity and 
mortality, followed by other complications such as native valve 
infective endocarditis, systemic embolisation, pulmonary hyper-
tension, atrial arrhythmias, or complications related to valve 
surgery.(26-32)
The leading cause of heart failure in the forms of RHD typically 
seen in Africa affecting young individuals in their fi rst or second 
decades is valve regurgitation mainly of the mitral and aortic 
valves.(26,28) It is common clinical course for RF and RHD to result 
in death in these young individuals(28) and the reasons for this 
malignant course are not entirely clear, but may partly be related 
to recurrent episodes of RF with inadequate secondary prophyl-
axis and multivalvular involvement.(28) Delayed clinical presentation 
also contributes to high morbidity and mortality.(32)
The mechanism of mitral valve regurgitation is related to 
infl ammation of the mitral valve apparatus leading to dilatation of 
the mitral anulus and elongation of the chordae and leafl ets which 
results in prolapse of the anterior mitral leafl et.(26,33) Aortic valve 
regurgitation, and less commonly tricuspid valve and pulmonary 
valve regurgitation are also related to infl ammation of the valve 
leafl ets and anuli.(34) The presence of mixed valve regurgitation 
and stenosis or pure valve stenosis is more common in older 
individuals with chronic and less active rheumatic carditis.(26,34)
Infective endocarditis is a devastating sequelae of RHD where 
RHD accounts for up to 76.6% of the underlying predisposing 
condition in some studies.(35) Again, those affected by infective 
endocarditis are typically young where morbidity and mortality 
are high due largely to new or worsening heart failure or 
neurologic complications.(27,35,36) In the 3-year prospective epidemi-
ology study of infective endocarditis, Koegelenberg and colleagues 
found a six month mortality of 35.6%.(35)
Rheumatic valve diseases, namely mitral valve stenosis with or 
without regurgitation, is the most common underlying cardiac 
condition complicating pregnancies in young women in Africa(37,38) 
with a maternal mortality rate of up to 9.5%.(39) It is not unusual 
for the diagnosis of RHD to be made for the fi rst time late 
during pregnancy(40) and the attendant consequences of late 
diagnosis are serious for both mother and child(40,41) Nqayana and 
colleagues recently published a retrospective review of all patients 
admitted with cardiac disease in pregnancy over a 1-year period at 
their tertiary hospital.(42) RHD (mitral valve disease) was the 
commonest aetiology of cardiac disease in the 95 patients included 
with the majority aged 21-25 years. There was high maternal 
morbidity with 13 patients admitted in cardiac failure, 9 with atrial 
fi brillation, 3 required intensive-care management, 8 required 
balloon mitral valvuloplasty and 1 underwent valve replacement at 
32 weeks’ gestation.(42) There were adverse fetal outcomes with 
14
86 live births of the 97 deliveries due largely to problems with anti-
coagulation.(42) 
INCIDENCE AND PREVALENCE OF RF AND RHD    
IN AFRICA
The number of new cases of RF per 100 000 per year in Tunisia 
was 30 in 1990 and in Algeria 11, 1 in 1997 and 6.2 in 2000.(43,44) 
There are no reliable data on the number of new cases of RF per 
year in sub-Saharan Africa(45) and the estimated 13 per 100 000 per 
year is based on incidence rates from the Middle East and North 
Africa.(43) Identifying new cases of RF demands active surveillance 
systems which requires enough skilled manpower and other 
resources such as laboratories which do not exist in many parts 
of Africa.(2) The World Health Organisation (WHO) has however 
demonstrated previously that setting up such surveillance systems 
is feasible in Africa, but that such systems falter operationally over 
time.(46)
The WHO estimated that there were 12 million people world-
wide in 1994 with RF and RHD, the majority of them in developing 
countries.(2) An update of the worldwide burden of RF and 
RHD estimated that 15.6-19.6 million people were affected by 
RHD with 2.4 million of those being children in the age group 
5-14 years.(4,43) Forty-two percent of the estimated 2.4 million 
children affected by RHD are located in sub-Saharan Africa. 
The number of people with previous RF who need secondary 
prophylaxis was estimated to be 1.88 million and the estimated 
number of deaths per year from RHD based on an annual mortality 
of 1.5% per year was 233 364-294 398.(4) 
The prevalence of RHD in the update was estimated to be 
highest in sub-Saharan Africa with a prevalence of 5.7 per 1 000, 
compared to 1.8 per 1 000 in North Africa, 2.2 per 1 000 in South 
central Asia and 0.3% in developed countries.(4) These estimates 
were based on large population-based data from the 1980s and 
1990s where school age children were screened for RHD by 
clinical examination confi rmed by echocardiographic and Doppler 
studies in some studies.(4,47,48)
Previous studies in school children on prevalence of RHD utilising 
clinical screening plus or minus echocardiography show variation 
in the prevalence of RHD from region to region within Africa(4) 
ranging from 1.0 per 1 000 in Inanda, South Africa to as high as 
14.0 per 1 000 in Kinshasa, Democratic Republic of Congo and 
14.6 per 1 000 Lusaka, Zambia.(6,43) These studies have also shown 
that the prevalence of RHD is higher in poorer communities as 
demonstrated by the study in Addis Ababa, Ethiopia where the 
prevalence of RHD was 1.0 per 1 000 in children of high socio-
economic status compared to 7.1 per 1 000 in those of low 
socio-economic status.(49)
A seminal epidemiologic study on the prevalence of RHD in Africa 
in school children was recently conducted and was published by 
Marijon and colleagues in the New England Journal of Medicine in 
2007.(7) The study was conducted from May through October 
2005 where 2 170 children age 6 to 17 years were randomly 
selected from six public primary schools among the 1 140 000 
children living in the capital city Maputo in Mozambique.(7) 
All children underwent a detailed clinical examination performed 
by physicians experienced in the diagnosis of murmurs and RHD 
and all children underwent a detailed echocardiographic 
examination.(7) Only left-sided valves were assessed for features 
of RHD. Echocardiographic criteria for RHD were the presence 
of any defi nite evidence of mitral or aortic regurgitation in two 
planes accompanied by at least two of the following morphologic 
abnormalities: restricted leafl et mobility, focal or generalised valve 
thickening, and abnormal subvalvular thickening.(7) Children who 
were found to have an organic murmur by clinical examination and 
RHD was confi rmed by echocardiography were classifi ed as having 
clinically detected RHD.(7)  
The fi ndings of the study were striking with respect to both 
the overall prevalence of RHD found in the children as well as the 
gross underestimation of RHD prevalence by clinical examination 
alone. Out of 2 170 children enrolled, 3 had a prior history of 
acute RF, 1 had known RHD, and only 2 were found to have acute 
RF.(7) The number of cases of RHD detected by clinical examina-
tion alone was 5 (2.3 per 1 000 children), and by echocardio-
graphic examination 66 (30.4 per 1 000), and by echocardio
graphic examination but not clinical examination 61 (28.1 per 
1 000).(7) Therefore, 92.4% of the cases of rheumatic valve 
diseases were clinically silent and occurred in children who 
were asymptomatic without an audible murmur.(7) By extension, 
of the 1 140 000 children age 6-17 years in Maputo, an estimated 
2 622 cases of RHD would be detected by clinical screening 





















ECHOCARDIOGRAPHIC SCREENING OF                  
VALVE DISEASE
Echocardiographic directed screening of valve diseases will 
undoubtedly uncover substantially higher prevalence of RHD 
across the continent. The geographic distribution will likely be 
similar to what has been documented, namely that the burden of 
disease will be highest in poorer countries and communities. 
Subclinical valve diseases in all stages of RF is not uncommon(50-52) 
and is not necessarily transient as demonstrated by Figueoa and 
colleagues in Chile, South America, in a long-term prospective 
follow up study of patients with subclinical rheumatic valvu-
litis.(53) Although there is a lack of data in Africa documenting 
the incidence of echocardiographically detected subclinical disease 
in cases of acute RF, the study by Marijon and colleagues in 
Mozambique sheds light on what appears to be an enormous 
problem of subclinical valve disease.(7) The argument against the 
standard use of echocardiography to detect valve diseases in 
Africa centers around cost, lack of equipment and echocardio-
graphic expertise, and potential over diagnosis of valve disease 
when physiologic regurgitation is found.(2) However, the counter 
argument for the use of echocardiographic screening and 
diagnosing of RHD in high prevalent settings is being correctly 
advanced by some.(2,17,53,54) Echocardiography is superior to physical 
examination in diagnosing valve disease and it makes sense to try 
to fi nd models and establish guidelines for proper application of 
echocardiography for the sake of determining true incidence and 
prevalence of disease and to identify cases needing secondary 
prophylaxis.(7,17)
PREVENTION AND MANAGEMENT OF                      
VALVE DISEASES
The prevention and control of RF and RHD in Africa is now 
a priority. The Pan African Society of Cardiology (PASCAR) 
convened a workshop in 2005 to frame a road map and action 
plan for the prevention and elimination of RF and RHD in Africa 
during this lifetime.(5,55) The action plan adopted at the workshop 
was called the Awareness Surveillance Advocacy Prevention 
(ASAP) Programme(56) which aims to (1) raise general awareness 
about RF and RHD (2) establish surveillance systems for the 
detection and treatment of cases of RF and RHD (3) champion 
advocacy for RF and RHD and (4) implement proven primary and 
secondary prevention strategies. 
The road to achieving the goal of eradicating RF and RHD has 
obvious barriers.(56) There is widespread lack of awareness about 
the causes, symptoms, risks and other problems associated with 
RF and RHD.(56) Part of this may be related to coexistent high 
rates of other public health problems such as HIV/AIDS, malaria, 
and tuberculosis which shift attention away from RF and RHD(17,56) 
However, even those affected by RF and RHD often do not 
receive adequate education or do not understand much of what 
they are told about the illness.(57) Setting up surveillance systems 
to capture new cases and regularly follow identifi ed cases requires 
concerted coordinated effort by an aware, dedicated and well 
supported health care system with laboratory capabilities.(2) 
Advocacy for RF and RHD faded largely due to the virtual 
disappearance of these diseases in developed nations and the lack 
of reliable epidemiologic data in Africa and other developing 
countries that highlight RF and RHD as major public health 
problems.(17,56) 
Primary prevention requires timely treatment of suspected or 
confi rmed GABHS to prevent RF, but laboratory confi rmation of 
GABHS remains the gold standard and these laboratory capabilities 
are not readily available.(2) Rapid diagnostic kits are helpful, but 
cannot substitute for a laboratory and a negative kit result requires 
laboratory confi rmation.(58)  It is recommended that in communities 
where RF is endemic,  all cases of sore throat in children 3-15 years 
old be treated as GABHS pharyngitis unless there is ulceration, 
or hoarseness, or watery nasal congestion, and/or conjunctivitis 
which argue against GABHS pharyngitis.(59) The WHO Acute 
Respiratory Infection Guideline lacks sensitivity for the diagnosis 
of GABHS pharyngitis since it requires both pharyngeal exudate 
and tender, enlarged lymph nodes to make the diagnosis.(60) 
Complicating primary prevention strategies is the absence of 
symptoms of pharyngitis in a signifi cant proportion of those who 
develop RF.(61)
Secondary prevention is the long-term administration of penicillin 
after the fi rst episode of RF to prevent recurrence and duration 
of treatment is tailored to the presence and severity of valve 
disease according to the WHO recommendations.(2,59) Secondary 
prevention is the strategy so far proven most cost effective in 
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the control of RF and RHD and is the main strategy supported 
by the WHO.(2) This strategy requires identifi cation of cases 
and establishment of registries of patients to ensure continued 
coordinated administration of antibiotics every 3-4 weeks.(2) 
However, whether administration of secondary prevention for all 
children with echocardiographically detected subclinical valve 
disease is warranted has not been shown.(54) 
 
Valve surgery is the way to managed valve disease causing heart 
failure, unless the risk is deemed to high. The diffi culties associated 
with valve surgery in Africa are immediately apparent. The 
majority of the patients needing valve surgery are young and 
poor and availability of surgical resources and expertise is not 
widespread.(62) Tissue prosthesis are not durable in young 
patients(63) and mechanical prosthesis are complicated by 
inadequate anticoagulation due to diffi culties with follow up, 
thromboembolic events, hemorrhage, or infective endocarditis.(64) 
Mitral valve repair is preferable to mitral valve replacement and 
is feasible in a number of patients, but there is risk of needing 
reoperation, particularly if valve repair is performed in the 
presence of active rheumatic carditis.(65) Cardiopulmonary bypass 
during pregnancy is associated with high fetal loss.(66) Mitral 
valve replacement during pregnancy, if deemed the only option, 
should be delayed until after delivery whenever possible.(66,67)    
Options for management of symptomatic mitral stenosis re-
fractory to medical therapy and particularly complicating 
pregnancy include percutaneous balloon valvotomy or closed 
mitral commissurotomy.(67-69) Mitral balloon valvotomy is preferred 
for severe mitral stenosis with pliable leafl ets and without heavy 
commissural calcifi cation,(68) but closed mitral commissurotomy, 
which can be performed without need for cardiopulmonary 
bypass, remains a viable options when balloon valvotomy cannot 
be performed.(69) 
NON-RHEUMATIC VALVE DISEASE                              
Other forms of valve disease previously reported in Africa include 
myxomatous mitral valve disease, age-related valve disease, sub-
valvular aneurysms, and valve disease related to endomyocardial 
fi brosis. Myxomatous mitral valve disease was fi rst described in 
South Africa by Barlow and Bosman in 1966(70) and is charact-
erised by variable myxomatous degeneration of the mitral valve 
leafl ets and chordae associated with mitral leafl et prolapse or 
fl ail leafl ets and mitral regurgitation. Myxomatous mitral valve 
disease is the leading indication for mitral valve surgery in 
developed countries,(71) but is an uncommon indication for 
mitral valve surgery in surgical series reported from Africa.(6) 
Valve diseases related to aging are the most common form of 
valve diseases in developed countries,(72) and are also en-
countered in the elderly in Africa.(73) However, age-related valve 
diseases of clinical signifi cance were not part of the spectrum of 
heart disease and risk factors in a recent cohort study of a large 
black urban population in Soweto, South Africa.(74) Congenital 
subvalvular aneurysms are rare and were also fi rst described in 
Africa.(75,76) These aneurysm may be located below the mitral 
or aortic valve and be associated with regurgitation, systemic 
embolisation, or rupture and are thought to be related to con-
genital weakness between the muscular ventricular wall and 
fi brous skeleton of the valve annulus.(77) The cause of endomyo-
cardial fi brosis is not well understood, but it is the most common 
cause of restrictive cardiomyopathy worldwide caused by deposi-
tion of fi brous tissue on endocardial surfaces causing heart failure 
associated with atrioventricular valve regurgitation.(78,79) There is 
no medical therapy for this illness and surgical results of advanced 
disease are poor.(79) Mocumbi and colleagues recently performed 
a large transthoracic echocardiographic survey in a rural area of 
Mozambique and found a high prevalence of endomyocardial 
fi brosis of 19.8%.(79) Most of those affected had mild-to-moderate 
abnormalities and it is hoped that early detection of disease with 
echocardiography will help in the study of the pathogenesis and 
in the development of new management strategies of this 
common disease.(79)
CONCLUSION                                                                 
Valve diseases are common and are a serious public health problem 
in Africa. Recent epidemiologic data suggests the prevalence of 
valve disease is underestimated. More epidemiologic data utilising 
echocardiographic detection of valve disease is needed to defi ne 
the full extent of the problem. The bulk of valve diseases are 
preventable and controllable through primary and secondary 
prevention measures, but these have not been implemented 
fully in Africa. PASCAR has appropriately created a sense of 
urgency in the efforts to eradicate RF and RHD and their efforts 
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